WideCells Group

Annual Report and Accounts 2016 & AGM

News Release | Newsroom

2 May 2017

WideCells Group PLC (‘WideCells Group’ or ‘the Company’) 

Annual Report and Accounts for the year ended 31 December 2016 and Notice of Annual General Meeting

WideCells Group PLC (‘WideCells’ or the ‘Company’), the healthcare services company focused on providing stem cell services and ground breaking insurance for stem cell treatment, announces that its Annual Report and Accounts for the year ended 31 December 2016 and a Notice of Annual General Meeting (“AGM”) have been posted to shareholders and are available to download on the Company’s website at http://www.widecellsgroup.com/.

The AGM will be held on 22 June 2017 at the Core Technology Facility, 46 Grafton Street, Manchester, M13 9NT at 12.00 noon.



For further information, please visit the Company’s website www.widecellsgroup.com, follow us on Twitter @WideCells_Group or contact:

WideCells Group PLC

CEO – João Andrade

Tel:  +351 919 033 171

Smaller Company Capital LLP

Broker – Jeremy Woodgate & Rupert Williams

Tel: +44 (0) 20 3651 2912

Shard Capital Partners LLP

Broker – Damon Heath & Erik Woolgar

Tel: +44 (0) 207 186 9950

St Brides Partners Ltd

PR – Elisabeth Cowell & Charlotte Page

Tel: +44 (0) 20 7236 1177

Notes to Editors

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. The Directors believe that the use of cord blood stem cells for transplant will drive one of the next important phases in medicine and is therefore developing market leading products in complementary, strategic areas which are designed to take advantage of substantial market opportunities in one of the fastest growing segments in the healthcare industry.  With this in mind, it has created three divisions:

  • CellPlan: the world’s first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.
  • WideCells: the Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to focus on stem cell research and regenerative medicine. WideCells also has international cryogenics divisions specialising on stem cell storage.
  • WideAcademy: developing an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow – WideCells will focus on promoting the collection and storage of this.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.
  • 82 illnesses can currently be treated using stem cell procedures.
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands.

This announcement contains inside information for the purposes of Article 7 of MAR. 


WideCells Group PLC